About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in the Denali team with a proposal to spin out the small-molecule drugs with ...

Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing several programs—and an executive—from Denali Therapeutics.

The biotech, called Tenvie Therapeutics, launched Wednesday with $200 million from ARCH Venture Partners — one of Denali’s early investors — as well as F-Prime Capital, Mubadala Capital ...

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tenvie Therapeutics launched today with a commitment to transform the treatment of neurological diseases. The company combines a deep ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Stoke Therapeutics has finalized plans for a Phase ...

The company is advancing a pipeline of therapeutics, including programs acquired from Denali Therapeutics Inc., focused on treating neurological, cardiometabolic and ophthalmic diseases.

Tenvie Therapeutics Inc. is getting a set of small-molecule drugs — specifically, ones aimed at tamping down inflammation, rescuing metabolic dysfunction and restoring lysosomal function ...

ARCH Venture Partners, F-Prime Capital, and Mubadala Capital lead $200 million investment to fuel acceleration of Tenvie into a multi-clinical asset company SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 ...

ARCH Venture Partners, F-Prime Capital, and Mubadala Capital lead $200 million investment to fuel acceleration of Tenvie into a multi-clinical asset company SOUTH SAN FRANCISCO, Calif., ...